



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

May 22, 2019

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir,

Subject: SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144—Fund raising by issuance of Debt Securities by Large Entities

With reference to the above subject, we would like to confirm that our Company is not falling under Large Corporate (LC) category as per the framework provided in the aforesaid circular.

We are enclosing herewith a NIL disclosure in Annexure A as per the prescribed format.

You are requested to take note of the same in your records.

Thanking you.

Yours sincerely,

For Novartis India Limited



Trivikram Guda
Company Secretary &
Compliance Officer

Encl.: as above

Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1	Name of the company	Novartis India Limited
2	CIN	L24200MH1947PLC006104
3	Outstanding borrowing of company as on 31st March,2019	Nil
4	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	N.A.
5	Name of Stock Exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	N.A.

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.



Trivikram Guda
Company Secretary



Monaz Noble
Whole time Director & CFO

Contact Details- Novartis India Limited
Inspire- BKC, Part of 601 and 701
Bandra Kurla Complex, Bandra (East),
Mumbai- 400051

Contact Details- Novartis India Limited
Inspire- BKC, Part of 601 and 701,
Bandra Kurla Complex, Bandra (East)
Mumbai- 400051

Date- 22.05.2019